Randomized trial of lifestyle modification and pharmacotherapy for obesity

被引:537
作者
Wadden, TA
Berkowitz, RI
Womble, LG
Sarwer, DB
Phelan, S
Cato, RK
Hesson, LA
Osei, SY
Kaplan, R
Stunkard, AJ
机构
[1] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[3] Brown Med Sch, Providence, RI USA
[4] GlaxoSmithKline Inc, Philadelphia, PA USA
[5] GlaxoSmithKline Inc, Bryn Mawr, PA USA
关键词
D O I
10.1056/NEJMoa050156
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Weight-loss medications are recommended as an adjunct to a comprehensive program of diet, exercise, and behavior therapy but are typically prescribed with minimal or no lifestyle modification. This practice is likely to limit therapeutic benefits. Methods In this one-year trial, we randomly assigned 224 obese adults to receive 15 mg of sibutramine per day alone, delivered by a primary care provider in eight visits of 10 to 15 minutes each; lifestyle-modification counseling alone, delivered in 30 group sessions; sibutramine plus 30 group sessions of lifestyle-modification counseling (i.e., combined therapy); or sibutramine plus brief lifestyle-modification counseling delivered by a primary care provider in eight visits of 10 to 15 minutes each. All subjects were prescribed a diet of 1200 to 1500 kcal per day and the same exercise regimen. Results At one year, subjects who received combined therapy lost a mean (+/-SD) of 12.1+/-9.8 kg, whereas those receiving sibutramine alone lost 5.0+/-7.4 kg, those treated by lifestyle modification alone lost 6.7+/-7.9 kg, and those receiving sibutramine plus brief therapy lost 7.5+/-8.0 kg (P<0.001). Those in the combined-therapy group who frequently recorded their food intake lost more weight than those who did so infrequently (18.1+/-9.8 kg vs. 7.7+/-7.5 kg, P=0.04). Conclusions The combination of medication and group lifestyle modification resulted in more weight loss than either medication or lifestyle modification alone. The results underscore the importance of prescribing weight-loss medications in combination with, rather than in lieu of, lifestyle modification.
引用
收藏
页码:2111 / 2120
页数:10
相关论文
共 32 条
[1]   The efficacy and safety of sibutramine for weight loss - A systematic review [J].
Arterburn, DE ;
Crane, PK ;
Veenstra, DL .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) :994-1003
[2]  
Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1
[3]   Short-term effects of sibutramine (Reductil™) on appetite and eating behaviour and the long-term therapeutic outcome [J].
Barkeling, B ;
Elfhag, K ;
Rooth, P ;
Rössner, S .
INTERNATIONAL JOURNAL OF OBESITY, 2003, 27 (06) :693-700
[4]   Behavior therapy and sibutramine for the treatment of adolescent obesity - A randomized controlled trial [J].
Berkowitz, RI ;
Wadden, TA ;
Tershakovec, AM ;
Cronquist, JL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14) :1805-1812
[5]   Double-blind randomized placebo-controlled trial of sibutramine [J].
Bray, GA ;
Ryan, DH ;
Gordon, D ;
Heidingsfelder, S ;
Cerise, F ;
Wilson, K .
OBESITY RESEARCH, 1996, 4 (03) :263-270
[6]  
BRIGHTWELL DR, 1979, INT J OBESITY, V3, P141
[7]  
Brownell KD, 1998, LEARN PROGRAM WEIGHT, V7
[8]  
BROWNELL KD, 1999, LEARN PROGRAM WEIGHT
[9]  
BROWNELL KD, 1990, WEIGHT MAINTENANCE S
[10]   Valvular heart disease associated with fenfluramine-phentermine [J].
Connolly, HM ;
Crary, JL ;
McGoon, MD ;
Hensrud, DD ;
Edwards, BS ;
Edwards, WD ;
Schaff, HV .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588